Table 1. Clinical data for patients included in the MiLEs-2 cohort.
Data presented as medians (Interquartile range [IQR]) or N (%).
| Variable | IPF | CF | COPD | CTD-ILD |
|---|---|---|---|---|
| N | 62 | 20 | 20 | 15 |
| Age (years), median (IQR) | 64.5 [60.0, 69.0] | 29.0 [23.8, 35.0] | 62.0 [59.0, 65.0] | 63.0 [54.0, 68.5] |
| Male, n (%) | 50 (81%) | 7 (35%) | 9 (45%) | 7 (47%) |
| Ever-smokers, n (%) | 42 (68%) | 0 (0%) | 20 (100%) | 10 (67%) |
| Total pack-years, median (IQR) | 10.2 [0.0, 30.0] | 0.0 [0.0, 0.0] | 57.5 [40.0, 65.5] | 10.0 [0.0, 26.8] |
| FEV1 (L), median (IQR) | 1.5 [1.2, 2.0] | 0.7 [0.6, 0.9] | 0.6 [0.5, 0.7] | 1.4 [1.2, 1.6] |
| FEV1 predicted %, median (IQR) | 53.0 [43.0, 67.0] | 22.0 [18.8, 24.2] | 25.0 [22.0, 30.2] | 52.0 [45.5, 68.0] |
| FVC (L), median (IQR) | 1.8 [1.4, 2.5] | 1.4 [1.1, 1.8] | 2.0 [1.8, 2.3] | 1.7 [1.5, 2.1] |
| FVC predicted %, median (IQR) | 41.0 [37.0, 58.0] | 32.5 [28.0, 41.2] | 58.5 [48.0, 66.0] | 47.0 [39.2, 60.2] |
| DLCO (ml), median (IQR) | 6.4 [4.7, 9.3] | 12.8 [11.8, 14.6] | 6.8 [5.1, 9.9] | 5.1 [4.6, 7.5] |
| DLCO predicted %, median (IQR) | 30.0 [22.0, 36.0] | 58.0 [49.0, 67.0] | 32.5 [26.8, 51.0] | 25.0 [20.5, 28.5] |
| Mean PAP (mmHg), median (IQR) | 24.0 [20.0, 28.0] | 25.0 [21.0, 33.0] | 21.5 [19.0, 27.0] | 24.5 [21.0, 38.8] |
| GERD#, n (%) | 48 (77%) | 19 (95%) | 12 (60%) | 15 (100%) |
| Systemic steroids, n (%) | 15 (24%) | 9 (45%) | 6 (30%) | 9 (60%) |
| Inhaled corticosteroids, n (%) | 11 (18%) | 8 (40%) | 19 (95%) | 5 (33%) |
| Specific therapies: | ||||
| Pirfenidone, n (%) | 10 (16%) | 0 (0%) | 0 (0%) | 1 (7%) |
| Nintedanib, n (%) | 9 (15%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Other immunomodulator, n (%) | 15 (24%) | 0 (0%) | 1 (5.0%) | 9 (60%) |
| BAL + culture or recipient tissue culture*, n (%) | 7 (12%)$ | 20 (100%) | 7 (35%) | 2 (13%)$ |
| Diffuse alveolar damage on explant pathology, n (%) | 21 (36%)$ | 0 (0%) | 0 (0%) | 5 (33%) |
| Antibiotics in past 3 months, n (%) | 25 (40%) | 20 (100%) | 9 (45%) | 9 (60%) |
| Lung transplant, n (%) | 47 (76%) | 20 (100%) | 20 (100%) | 10 (67%) |
GERD definition: based on clinical history, available data from esophagogram or upper endoscopy, or prescription for proton pump inhibitor or histamine receptor 2 blocker.
Systemic steroids refers to patients receiving systemic steroids at the time of the hospital admission resulting in transplant or death.
All patients who underwent lung transplantation had a tissue culture of their resected main stem bronchial tissue, as per the institutional transplant protocol.
Lung transplant, n (%) indicates the number of patients with native lungs sampled at the time of transplant, rather than at autopsy.
Percentage calculated with denominator of all patients with available data (patients with unavailable data for each variable were removed from calculations).
Abbreviations: FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; DLCO: diffusion capacity of the lungs for carbon monoxide; GERD: gastroesophageal reflux disease; PAP: pulmonary artery pressure.